These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24184025)

  • 1. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
    Schutz FA; Xie W; Donskov F; Sircar M; McDermott DF; Rini BI; Agarwal N; Pal SK; Srinivas S; Kollmannsberger C; North SA; Wood LA; Vaishampayan U; Tan MH; Mackenzie MJ; Lee JL; Rha SY; Yuasa T; Heng DY; Choueiri TK
    Eur Urol; 2014 Apr; 65(4):723-30. PubMed ID: 24184025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    Kawashima A; Tsujimura A; Takayama H; Arai Y; Nin M; Tanigawa G; Uemura M; Nakai Y; Nishimura K; Nonomura N;
    Int J Urol; 2012 Dec; 19(12):1050-7. PubMed ID: 22860625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact.
    Penttilä P; Bono P; Peltola K; Donskov F
    Acta Oncol; 2018 Nov; 57(11):1580-1585. PubMed ID: 29863419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
    Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
    Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
    Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
    Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
    Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
    Saad E; Gebrael G; Semaan K; Eid M; Saliby RM; Labaki C; Sayegh N; Wells JC; Takemura K; Ernst MS; Lemelin A; Basappa NS; Wood LA; Powles T; Ernst DS; Lalani AA; Agarwal N; Xie W; Heng DYC; Choueiri TK
    Oncologist; 2024 Aug; 29(8):699-706. PubMed ID: 38630540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
    Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
    Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
    Kroeger N; Xie W; Lee JL; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Kollmannsberger CK; Tan MH; North SA; Rini BI; Choueiri TK; Heng DY
    Cancer; 2013 Aug; 119(16):2999-3006. PubMed ID: 23696129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.